Included in the formulation
АТХ:A.10.B.X.10 Lixisenatide
Pharmacodynamics:Selectively interacts with receptors of glucagon-like peptide-1, which leads to an increase in the content of cAMP within the cell. As a result, glucagon-dependent secretion of insulin is stimulated by β-cells of the islets of Langerhans.
Stimulates the production of insulin β-cells in hyperglycemia. With a normal amount of glucose in the blood plasma stops stimulating the secretion of insulin. In a state of hyperglycemia, it suppresses the secretion of glucagon, while maintaining a protective reaction to increase glucagon production in hypoglycemia.
Slows down the evacuation of the stomach, reducing the rate of increase in glucose concentration after meals. Promotes weight loss.
Pharmacokinetics:After subcutaneous administration, the maximum concentration in the blood plasma is achieved after 1-3.5 hours. The connection with plasma proteins is 55%.
Metabolism in the liver and kidneys by enzyme proteolysis.
The half-life is 1.5-4.5 hours. Elimination by the kidneys.
Indications:It is used for the treatment of diabetes mellitus II type in combination with oral hypoglycemic agents and basal insulin.
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
Contraindications:Diabetes I type (insulin-dependent), coma, ketoacidosis, severe renal failure, gastroparesis, pregnancy and lactation, age under 18, individual intolerance.
Carefully:Pancreatitis in the anamnesis.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously in the area of the shoulder, hip and anterior abdominal wall 1 time per day. The drug is used for 1 hour before a morning or evening meal of 10 or 20 mcg (depending on the level of hyperglycemia).
The highest daily dose: 20 mcg.
The highest single dose: 20 mcg.
Side effects:Central and peripheral nervous system: headache, dizziness.
Respiratory system: upper respiratory tract infection, influenza.
Digestive system: dyspepsia, nausea, vomiting, diarrhea, hepatitis, cholestatic jaundice.
Musculoskeletal system: low back pain.
Dermatological reactions: a rash.
Urinary system: proteinuria.
Allergic reactions.
Overdose:Increased side effects, mainly from the digestive system.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:The syringe pen contains 14 doses. After the activation of the cartridge, the shelf life of the drug is 14 days.